Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | XIAP | P98170 | 1/20 | 0.56 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 5/20 | 0.47 |
| ▸ | ALOX5AP | P20292 | 6/20 | 0.46 |
| ▸ | FEN1 | P39748 | 6/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7125712 | 0.92 | THRB (0.45) | KDM4EALDH1A1ALOX15TSHRXIAP | |
| SCHEMBL7125640 | 0.83 | LMNA (0.51) | THRBALOX5APFEN1LMNAMAPT | |
| SCHEMBL7117717 | 0.82 | MAPT (0.48) | THRBALOX5APFEN1LMNAMAPT | |
| SCHEMBL7117836 | 0.79 | ALOX5AP (0.51) | ALOX5APFEN1 | |
| SCHEMBL7122641 | 0.77 | GAA (0.43) | THRBLMNAMAPT | |
| SCHEMBL7128378 | 0.77 | GAA (0.43) | THRBLMNAMAPT | |
| SCHEMBL7128783 | 0.74 | ALOX5AP (0.47) | ALOX15ALOX5APFEN1 | |
| SCHEMBL17357510 | 0.73 | ALOX15 (1.00) | KDM4EALDH1A1ALOX15TSHRXIAP | |
| SCHEMBL18360796 | 0.73 | ALOX15 (1.00) | KDM4EALDH1A1ALOX15TSHRXIAP | |
| SCHEMBL31278555 | 0.73 | ALOX15 (1.00) | KDM4EALDH1A1ALOX15TSHRXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030114448-A1 | Inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. | 2003-06-19 | — | — | US | disclosed |
| WO-2002096873-A1 | ISOINDOLE AND ISOQUINOLINE DERIVATIVES AS INHIBITORS OF FACTOR XA | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114448-A1 | Inhibitors of factor Xa | SERPINC1, F11, TFPI | KDM4E 3179/4885ALDH1A1 3497/4885ALOX15 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.